Litigation Details for (EPP)Self Insured Schools of California v. Merck and Co Inc (E.D. Va. 2018)

(EPP)Self Insured Schools of California v. Merck and Co Inc (E.D. Va. 2018)

Docket	2:18-cv-01004	Date Filed	2018-06-21
Court	District Court, E.D. Virginia	Date Terminated	2019-05-07
Cause	15:1 Antitrust Litigation	Assigned To	Rebecca Beach Smith
Jury Demand	Plaintiff	Referred To	Douglas E. Miller
Patents	7,030,106; 7,612,058; RE37,721
Link to Docket	External link to docket

Details for (EPP)Self Insured Schools of California v. Merck and Co Inc (E.D. Va. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-06-21				External link to document
2018-06-21	1		issued as U.S. 4 Patent No. 7,030,106. According to Merck, the ’106 patent originally was set to …U.S. Patent No. 5,631,365 (“the ’365 15 patent”), U.S. Patent No. 5,767,115 (“the ’115 patent”), U.S… U.S. Patent No. 5,846,966 16 (“the ’966 patent”), the RE’721 reissue patent, and the RE’461 reissue… U.S. Patent No. 5,631,365. The ’365 patent was the first-issued 19 Merck azetidinone patent. The …. On May 28, 2002, the Patent 2 Office re-issued the patent as U.S. Patent No. RE37,721. 3	External link to document

EPP Self-Insured Schools of California v. Merck & Co Inc.: Antitrust Litigation Analysis

Last updated: February 19, 2026

Case Overview

EPP Self-Insured Schools of California (EPP) filed a class-action antitrust lawsuit against Merck & Co. Inc. (Merck) in the U.S. District Court for the Eastern District of Pennsylvania (EDPA) on February 8, 2018. The lawsuit, case number 2:18-cv-01004, alleges that Merck engaged in anticompetitive practices related to the sale of its human papillomavirus (HPV) vaccine, Gardasil. EPP, representing a class of direct purchasers of prescription drugs, claims Merck illegally maintained a monopoly over the Gardasil market and unlawfully extended its monopoly through anticompetitive conduct.

Allegations of Anticompetitive Conduct

The core of EPP's allegations centers on Merck's alleged abuse of its market dominance in the HPV vaccine sector. EPP contends that Merck achieved this dominance through several anticompetitive strategies:

• Predatory Pricing: EPP alleges Merck engaged in predatory pricing practices to drive out or prevent competition from other HPV vaccine manufacturers. This involved setting prices below cost for a sustained period to eliminate rivals, thereby creating a barrier to entry.
• Bundling and Loyalty Rebates: The lawsuit claims Merck used illegal bundling of Gardasil with other Merck products and offered loyalty rebates. These practices allegedly coerced purchasers, such as health insurers and large pharmacy benefit managers (PBMs), into exclusive purchasing agreements for Gardasil, excluding competing vaccines.
• Misleading Regulatory Filings: EPP asserts Merck made deceptive statements to regulatory bodies, including the U.S. Food and Drug Administration (FDA), to hinder the approval and market entry of competing HPV vaccines. This allegedly involved misrepresenting the efficacy, safety, or other characteristics of Gardasil or competitors' products.
• Patent Thickets and Sham Litigation: EPP claims Merck created a "patent thicket" around Gardasil, filing numerous overlapping patents. This strategy, coupled with allegedly baseless patent litigation against potential competitors, was designed to create legal uncertainty and deter market entry.

Legal Basis of the Lawsuit

EPP's claims are brought under federal antitrust laws, specifically the Sherman Act. The class action seeks to recover damages on behalf of all entities who purchased Gardasil directly from Merck during the relevant period. The damages sought are to compensate for the alleged overcharges and lost competition resulting from Merck's anticompetitive conduct.

Key provisions of the Sherman Act relevant to this case include:

• Section 1: Prohibits contracts, combinations, or conspiracies in restraint of trade. EPP alleges that Merck's bundling and rebate schemes constituted such agreements.
• Section 2: Prohibits monopolization or attempts to monopolize any part of trade or commerce. EPP's allegations of predatory pricing and patent thickets fall under this section.

Key Legal Filings and Rulings

The litigation has progressed through several critical stages.

Initial Complaint and Motions to Dismiss

EPP filed its initial complaint on February 8, 2018. Merck subsequently filed a motion to dismiss, arguing that EPP failed to state a plausible claim for relief and that the allegations were too speculative.

Class Certification

A significant development in the case was the court's decision on class certification. On July 27, 2020, the EDPA granted EPP's motion for class certification. This ruling allowed the case to proceed as a class action, representing a broad group of direct purchasers of Gardasil. The court found that common issues of law and fact predominated across the proposed class members, particularly concerning Merck's alleged monopoly and anticompetitive conduct.

Class Definition: The certified class generally includes all entities within the United States who purchased Gardasil directly from Merck or its distributors between February 8, 2014, and the present date of the order [2].

Discovery and Expert Testimony

Following class certification, the parties engaged in extensive discovery. This phase involved the exchange of documents, depositions of key personnel, and the submission of expert reports. Expert testimony focused on economic analysis of market power, pricing strategies, and the alleged impact of Merck's conduct on competition and purchasers.

Merck's Summary Judgment Motions

Merck has filed several motions for summary judgment, seeking to have claims dismissed before trial. These motions typically argue that there is no genuine dispute of material fact and that Merck is entitled to judgment as a matter of law. The court's rulings on these motions have been pivotal in shaping the path of the litigation.

For example, on January 26, 2023, the court denied Merck's motion for summary judgment on EPP's claims of unlawful monopolization under Section 2 of the Sherman Act. The court found sufficient evidence to allow a jury to consider whether Merck engaged in anticompetitive conduct that maintained its monopoly power in the HPV vaccine market [3]. However, the court granted summary judgment in favor of Merck on certain other claims, including allegations related to the Noerr-Pennington doctrine, which protects petitioning the government from antitrust liability, finding that EPP had not adequately demonstrated sham litigation or abuse of the regulatory process in those specific instances.

Current Status of the Litigation

As of the latest available information, the EPP v. Merck litigation remains active. The case has overcome significant procedural hurdles, including class certification and initial summary judgment motions. The central claims of monopolization and anticompetitive conduct are proceeding.

A trial date has not been definitively set, but the case is proceeding towards potential trial. The outcome will depend on the evidence presented regarding Merck's market practices and their impact on competition. The potential damages, if EPP prevails, could be substantial, given the market size for HPV vaccines and the duration of the alleged monopoly.

Comparative Analysis: Antitrust Litigation in Pharmaceuticals

The EPP v. Merck case is emblematic of broader antitrust challenges faced by pharmaceutical companies. Similar litigation has targeted other blockbuster drugs and vaccines, raising questions about pricing, market exclusivity, and innovation.

Key Themes in Pharmaceutical Antitrust Litigation:

• "Pay-for-Delay" Settlements: These involve brand-name drug manufacturers paying generic manufacturers to delay the launch of cheaper generic versions of a drug. While not directly at issue in EPP v. Merck, this is a common antitrust concern in the pharmaceutical sector.
• Evergreening of Patents: Companies file numerous secondary patents for minor modifications to extend the patent life of a drug, creating patent thickets similar to those alleged by EPP.
• Anticompetitive Rebate Programs: Large discounts and rebates offered by manufacturers to PBMs and insurers can incentivize them to favor certain drugs over others, potentially stifling competition.
• Misleading Marketing and Regulatory Practices: Allegations of deceptive practices in promoting drugs or interacting with regulatory agencies are also frequent grounds for antitrust lawsuits.

Comparison to Other Cases:

While each pharmaceutical antitrust case is unique, the EPP v. Merck lawsuit shares similarities with past and ongoing litigation. For instance, In re Pharmaceutical Industry Average Wholesale Price Litigation involved allegations of inflated drug prices through misrepresentations to government programs [4]. Cases like FTC v. Actavis, Inc. addressed "pay-for-delay" agreements in the generic drug market, establishing that such agreements could violate antitrust laws if they unreasonably restrained trade [5].

The EPP lawsuit, however, focuses specifically on the market for a single vaccine (Gardasil) and alleges a more direct monopolization strategy rather than solely focusing on indirect effects of pricing or settlement agreements. The emphasis on bundling, loyalty rebates, and the creation of patent thickets to maintain a monopoly over a specific product distinguishes it.

The success of EPP in this litigation could set precedents for how courts scrutinize the market exclusivity strategies of pharmaceutical companies, particularly for novel and widely adopted therapies like vaccines.

Potential Impact and Future Outlook

The ongoing litigation in EPP v. Merck carries significant implications for Merck and the broader pharmaceutical industry.

For Merck & Co. Inc.:

• Financial Exposure: A substantial adverse judgment could lead to significant monetary damages, impacting Merck's profitability and stock valuation. This includes potential treble damages under antitrust law.
• Reputational Damage: Prolonged antitrust litigation can negatively affect a company's public image and stakeholder trust.
• Strategic Adjustments: A loss could force Merck to re-evaluate its marketing, pricing, and patent strategies for current and future products.

For the Pharmaceutical Industry:

• Increased Scrutiny: The case may lead to heightened scrutiny of anticompetitive practices by antitrust regulators and private litigants.
• Shifts in Business Practices: Pharmaceutical companies might adapt their strategies concerning pricing, bundling, and patent portfolio management to mitigate antitrust risks.
• Incentives for Competition: Successful antitrust enforcement could encourage greater competition in markets dominated by a single product, potentially leading to lower prices and increased access for consumers.

The legal landscape for pharmaceutical antitrust litigation is complex and evolving. The EPP v. Merck case will be closely watched for its resolution, as it could influence market dynamics and business practices within the industry for years to come.

Key Takeaways

• EPP Self-Insured Schools of California has brought an antitrust class-action lawsuit against Merck & Co. Inc. concerning alleged anticompetitive practices related to the Gardasil HPV vaccine.
• The lawsuit alleges Merck unlawfully maintained a monopoly through predatory pricing, illegal bundling, loyalty rebates, misleading regulatory filings, and patent thickets.
• The U.S. District Court for the Eastern District of Pennsylvania certified the class of direct purchasers on July 27, 2020.
• The court denied Merck's motion for summary judgment on monopolization claims under Sherman Act Section 2 on January 26, 2023, allowing these claims to proceed to trial.
• The litigation highlights ongoing antitrust concerns in the pharmaceutical sector regarding market exclusivity and pricing strategies for high-value drugs and vaccines.

Frequently Asked Questions

1. What specific antitrust laws are being invoked in this case? The lawsuit is brought under Sections 1 and 2 of the Sherman Antitrust Act, which prohibit contracts, combinations, or conspiracies in restraint of trade and monopolization or attempts to monopolize, respectively.

2. What is the definition of the class that was certified? The certified class includes all entities within the United States who purchased Gardasil directly from Merck or its distributors between February 8, 2014, and the date of the class certification order on July 27, 2020.

3. Has Merck been found liable for any antitrust violations in this case? No, Merck has not been found liable. The court has denied Merck's motion for summary judgment on certain monopolization claims, meaning these claims will proceed, but no final determination of liability has been made.

4. What are the primary anticompetitive practices alleged by EPP? EPP alleges predatory pricing, illegal bundling of Gardasil with other Merck products, the use of loyalty rebates to secure exclusive purchasing arrangements, and the creation of extensive patent portfolios (patent thickets) to deter competition.

5. What is the current status of the litigation? The case is proceeding towards potential trial. The court has certified the class and denied Merck's motion for summary judgment on key monopolization claims, allowing these issues to be litigated further.

Citations

[1] EPP Self-Insured Schools of California v. Merck & Co. Inc., No. 2:18-cv-01004 (E.D. Pa. filed Feb. 8, 2018). [2] Order Granting Motion for Class Certification, EPP Self-Insured Schools of California v. Merck & Co. Inc., No. 2:18-cv-01004 (E.D. Pa. July 27, 2020). [3] Order Denying Defendant Merck & Co., Inc.’s Motion for Summary Judgment, EPP Self-Insured Schools of California v. Merck & Co. Inc., No. 2:18-cv-01004 (E.D. Pa. Jan. 26, 2023). [4] In re Pharmaceutical Industry Average Wholesale Price Litigation, 308 F. Supp. 2d 746 (D. Mass. 2004). [5] Federal Trade Commission v. Actavis, Inc., 570 U.S. 136 (2013).